[{"orgOrder":0,"company":"HK inno.N","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hk Inno.N Publishes P3 Trial Results of Drug on Gastric Ulcers","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"HK inno.N"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"High Infliximab Trough Levels Are Associated With Low Risk of Relapse When Switching to Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease, Suggests New Data Presented at ECCO 2022 Virtual Congress","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Celltrion"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dr. Reddy\u2019s Laboratories to Commercialise Novel Molecule Tegoprazan in India","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"HK inno.N"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Pharmaceutical Submitted NDA For Its Global New Drug Fexuclue in 11 Countries, only 1 Year After Approval in Korea","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Neurogastrx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daewoong Pharmaceutical Regaining Rights to Fexuprazan in the United States and Canada Upon Termination of License Agreement With Neurogastrx","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"COOPER PHARMA","pharmaFlowCategory":"D","amount":"$20.3 million","upfrontCash":"Undisclosed","newsHeadline":"Daewoong Pharmaceutical's Fexuprazan Takes its First Step into Africa Entering into a Partnership with Cooper Pharma, the No. 1 Pharmaceutical Company in Morocco in the Field of Digestive Health","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA\u00ae (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Celltrion"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approves Remsima\u2122 SC for the Treatment of Inflammatory Bowel Disease (IBD)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Celltrion"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Remsima (infliximab) blocks the action of TNF-alpha. It is approved for maintenance therapy in adults with moderately to severely active ulcerative colitis and crohn’s disease.
Zymfentra is the first and only FDA-approved subcutaneous (SC) formulation of infliximab approved for the maintenance treatment of adult patients with moderately to severely active ulcerative colitis and Crohn’s disease.
Under the agreement, Daewoong Pharmaceutical plans to expand its presence of a potassium-competitive acid blocker (P-CAB) drug Fexuclue (fexuprazan) in the African pharmaceutical market for gastroesophageal reflux disease (GERD).
Under the terms of the termination agreement, Daewoong regains all rights to the commercialization and clinical development of Fexuclue (fexuprazan), a novel potassium-competitive acid blocker for the treatment of erosive esophagitis, in the U.S. and Canada.
Fexuclue (fexuprazan) is a potassium-competitive acid blocker (P-CAB) drug. By improving the drawbacks of existing proton pump inhibitors (PPIs), it binds to the proton pump without activating gastric acid and quickly and stably inhibits the secretion of gastric acid.
Under this partnership, HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan (CJ-12420), while Dr. Reddy’s will be responsible for local clinical development, registration, marketing and sales in the licensed territories
Data from the RTDM study show infliximab drug levels are stable across a 14-day treatment cycle for Crohn’s disease patients in remission, under maintenance therapy with Remsima SC, enabling therapeutic drug monitoring to be performed at any time between the two SC injections.
In the study, cohorts with 50 and 100 milligrams of K-CAB tablets showed superior therapeutic effect and safety in treating gastric ulcers than the group administered with 30 milligrams of Lansoprazole.